Bayesian Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bayesian Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-19,900	Closed	-$2.54M	–	317
2026 Q1	$2.54M	Buy	+19,900	New	+$2.48M	3.1%	7
2025 Q1	–	Sell	-21,100	Closed	-$1.9M	–	1010
2024 Q4	$1.9M	Buy	+21,100	New	+$2.04M	0.23%	130
2024 Q3	–	Sell	-17,100	Closed	-$1.59M	–	1080
2024 Q2	$1.59M	Buy	17,100 +9,523	+126%	+$854K	0.18%	151
2024 Q1	$719K	Sell	7,577 -496	-6%	-$46K	0.07%	364
2023 Q4	$721K	Sell	8,073 -18,585	-70%	-$1.38M	0.08%	301
2023 Q3	$1.95M	Buy	+26,658	New	+$2.13M	0.22%	116
2023 Q1	–	Sell	-11,703	Closed	-$971K	–	1131
2022 Q4	$971K	Sell	11,703 -14,697	-56%	-$1.19M	0.14%	184
2022 Q3	$2.09M	Sell	26,400 -3,542	-12%	-$299K	0.42%	44
2022 Q2	$2.22M	Buy	+29,942	New	+$2.25M	0.41%	34
2022 Q1	–	Sell	-16,900	Closed	-$1.89M	–	944
2021 Q4	$1.89M	Buy	+16,900	New	+$2.04M	0.6%	35
2021 Q3	–	Sell	-7,400	Closed	-$1M	–	574
2021 Q2	$1M	Buy	+7,400	New	+$973K	0.26%	100
2020 Q4	–	Sell	-7,400	Closed	-$825K	–	689
2020 Q3	$825K	Buy	+7,400	New	+$830K	0.2%	133
2020 Q2	–	Sell	-4,548	Closed	-$352K	–	823
2020 Q1	$352K	Sell	4,548 -2,552	-36%	-$226K	0.08%	401
2019 Q4	$675K	Sell	7,100 -7,200	-50%	-$623K	0.12%	237
2019 Q3	$1.09M	Buy	+14,300	New	+$1.19M	0.21%	126
2019 Q1	–	Sell	-6,900	Closed	-$495K	–	789
2018 Q4	$495K	Buy	+6,900	New	+$556K	0.1%	287
2016 Q4	–	Sell	-3,200	Closed	-$212K	–	723
2016 Q3	$212K	Buy	+3,200	New	+$198K	0.14%	272

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Bayesian Capital Management's XBI Position: Q2 2026 in Review

Bayesian Capital Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2026, closing a stake of 19,900 shares — an estimated $2.54M sold.

Bayesian Capital Management first reported a position in XBI in Q3 2016 and held it in 17 quarters. The position peaked at $2.54M in Q1 2026. 932 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Bayesian Capital Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2026 after selling out during the quarter.
Bayesian Capital Management sold 19,900 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $2.54M.
Bayesian Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q3 2016 and held it in 17 quarters.
Bayesian Capital Management's State Street SPDR S&P Biotech ETF position peaked at $2.54M in Q1 2026.
932 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Bayesian Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.